Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers
Top Cited Papers
- 12 May 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 10 (8), 1121-1128
- https://doi.org/10.1158/2159-8290.cd-20-0596
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has led to dramatic changes in oncology practice. It is currently unknown whether PD-1 blockade therapy impacts severity of illness from COVID-19 in patients with cancer. To address this uncertainty, we examined consecutive patients with lung cancers who were diagnosed with COVID-19 and examined severity based on no or prior receipt of PD-1 blockade. Overall, the severity of COVID-19 in patients with lung cancer was high, including need for hospitalization in more than half of patients and death in nearly a quarter. Prior PD-1 blockade was, as expected, associated with smoking status. After adjustment for smoking status, PD-1 blockade exposure was not associated with increased risk of severity of COVID-19. PD-1 blockade does not appear to impact the severity of COVID-19 in patients with lung cancers.Funding Information
- Memorial Sloan-Kettering Cancer Center (P30-CA008748)
- NIH (T32-CA009207, K30-UL1TR00457)
- Damon Runyon Cancer Research Foundation (CI-98-18)
This publication has 32 references indexed in Scilit:
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJama-Journal Of The American Medical Association, 2020
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet Oncology, 2020
- Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanomaNature Medicine, 2020
- Aluminum Parts Fabricated by Laser-Foil-Printing Additive Manufacturing: Processing, Microstructure, and Mechanical PropertiesMaterials, 2020
- Can Immune Checkpoint Inhibitors Keep JC Virus in Check?The New England Journal of Medicine, 2019
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 responseNature, 2017
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapyNature, 2016
- Into the Eye of the Cytokine StormMicrobiology and Molecular Biology Reviews, 2012
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010
- Restoring function in exhausted CD8 T cells during chronic viral infectionNature, 2005